Ivonescimab Achieves OS Endpoint in Phase III Biliary Tract Cancer — First Success Beyond NSCLC
SMMT sits 16% above its 52-week low of $12.07.
Summary
Akeso's Phase III HARMONi-GI1 trial showed ivonescimab plus chemotherapy beat durvalumab plus chemotherapy on overall survival in first-line advanced biliary tract cancer — the first positive Phase III readout for the drug beyond NSCLC.
Key Events · Product Development and Regulatory · SMMT
-
HARMONi-GI1 Meets Primary OS Endpoint
Ivonescimab plus chemotherapy achieved statistically significant and clinically meaningful overall survival superiority over durvalumab plus chemotherapy in first-line advanced biliary tract cancer.
-
First Phase III Win Beyond NSCLC
This is the first Phase III readout for ivonescimab outside of non-small cell lung cancer, and the first known Phase III study in advanced BTC to demonstrate OS superiority versus an anti-PD-(L)1 plus chemotherapy regimen.
-
Secondary Endpoints Also Met
The study also met key secondary endpoints of progression-free survival and objective response rate, with detailed safety and efficacy data expected at an upcoming medical congress and peer-reviewed publication.
-
Fifth Positive Phase III Readout
Five Phase III ivonescimab trials have now read out with positive data — four in NSCLC and one in biliary tract cancer — broadening the drug's clinical profile across tumor types.
Analysis · SMMT · Life Sciences
Summit's partner Akeso reported that the Phase III HARMONi-GI1 trial met its primary endpoint, with ivonescimab plus chemotherapy demonstrating statistically significant and clinically meaningful overall survival superiority over durvalumab plus chemotherapy in first-line advanced biliary tract cancer. This marks the first Phase III readout for ivonescimab outside of NSCLC and the first known Phase III study in advanced BTC to beat an anti-PD-(L)1 plus chemotherapy regimen on OS. The result broadens the drug's clinical profile beyond lung cancer and adds a fifth positive Phase III readout across the program, reinforcing the molecule's potential across multiple tumor types. The data were generated and analyzed entirely by Akeso in China, where ivonescimab is already commercially available for NSCLC, but the signal is directionally supportive for Summit's global development strategy ahead of the November 14, 2026 PDUFA date for the NSCLC BLA.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 35.8% of the 1864 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SMMT was trading at $14.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.7B. The 52-week trading range was $12.07 to $30.05. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.